{
    "nctId": "NCT05878964",
    "briefTitle": "Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.",
    "officialTitle": "Evaluation of Skin Health and Quality of Life in Patients Receiving Anticancer Therapies Based on Monoclonal Antibody Anti-PD1/PDL1/CTLA4 or Cyclin-dependent Kinase (CDK) Inhibitors",
    "overallStatus": "RECRUITING",
    "conditions": "Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer, Gastric Cancer, Skin Cancer, Melanoma, Head Neck Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 420,
    "primaryOutcomeMeasure": "Quality of life in patients undergoing anti-PD1/PDL1/CTLA4 or cyclin-dependent kinase (CDK) inhibitors evaluated by EQ-5D-5L questionnaire.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n(for all Groups)\n\n1. Age \u2265 18 years.\n2. Histological diagnosis of solid tumor.\n3. Patient able to complete the questionnaires submitted during the study.\n4. Signed written informed consent. (for Group I) Patients already under treatment for at least three months with anti-PD1/PDL1/ CTLA4 or cyclin-dependent kinase (CDK) inhibitors for any type of cancer. Treatment considered for each cancer are only those approved by AIFA for each tumor.\n\n(for Group II) Patients eligible for treatment with anti-PD1/PDL1/ CTLA4 or cyclin-dependent kinase (CDK) inhibitors for any type of cancer. Treatment considered for each cancer are only those approved by AIFA for each tumor.\n\nExclusion Criteria (for all Groups):\n\n1. Age \\< 18 y.o.\n2. Skin diseases or alterations present before the beginning of anti-PD1/PDL1 or cyclin-dependent kinase (CDK) inhibitors.\n3. Chronic use of steroids.\n4. Previous psychiatric disorders or patients taking antidepressant.\n5. Refusal to sign written informed consent.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}